A review of IL-36: an emerging therapeutic target for inflammatory dermatoses. (18th August 2022)

• Record Type: Journal Article
• Authors: Hwang, Jonwei; Rick, Jonathan; Hsiao, Jennifer; Shi, Vivian Y.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 6(2022)
• Page Start: 2711
• Page End: 2722
• Publication Date: 2022-08-18
• Subjects: Psoriasis -- atopic dermatitis -- hidradenitis suppurativa -- IL-36 -- spesolimab -- imsidolimab; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2022.2067819
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background: IL-36 cytokines are members of the IL-1 superfamily. Increasing evidence in the IL-36 pathway demonstrates their potential as a therapeutic target for treating inflammatory skin diseases, such as generalized pustular psoriasis (GPP). Objective: A narrative review was written to further study preclinical and clinical evidence for the role of IL-36 in psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), acne, autoimmune blistering diseases, and neutrophilic dermatoses. Results: IL-36 has important downstream effects such as inducing expression of inflammatory cytokines, antimicrobial peptides, and growth factors. Increased expression of IL-36 cytokines has been observed in the lesional skin of patients with psoriasis. Studies of other inflammatory skin diseases have also noted similar findings, albeit to a lesser extent. IL-36 inhibition has been shown to be effective in GPP and is currently being studied for other inflammatory skin diseases. Conclusions: The IL-36 pathway contributes to pathogenesis of many inflammatory skin diseases and is a promising therapeutic target.